Compare Marsh & McLennan Companies, Inc. (MRSH) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marsh & McLennan Companies, Inc. vs GeneDx Holdings Corp — how do they compare? Marsh & McLennan Companies, Inc. trades at $175.76 (market cap $84.31B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 41.7× GeneDx Holdings Corp's market cap, and Marsh & McLennan Companies, Inc. pays a 2.24% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Marsh & McLennan Companies, Inc. for 109 Days and GeneDx Holdings Corp for 19 Days on average.
| MRSH | WGS | |
|---|---|---|
Market Cap | $84.31B | $2.02B |
Volume | 3,948,947 | 734,640 |
Sector | Financials | Health |
52-Week High | $207.02 | $167.51 |
52-Week Low | $157.32 | $34.51 |
Typical Hold Time | 109 Days | 19 Days |
Enterprise Value | $104.99B | $2.05B |
Dividend Yield | 2.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marsh (MRSH) trades at $176.67, up 1.73% today, near its consensus price target of $202.71. The stock shows a bullish technical trend with support at $174 and resistance at $178. Recent earnings beats and the acquisition of Accel Holdings highlight strong operational momentum. Revenue grew to $27.0B in 2025, with a net income margin of 14.24% and a P/E ratio of 21.57, indicating solid profitability amid moderate valuation.
The outlook remains positive with consistent earnings outperformance and strategic acquisitions driving growth. Risks include elevated debt levels and potential margin pressure. Analysts are mostly neutral (65% Hold), but the stock offers upside to the price target. Investors should weigh strong cash flow generation against macroeconomic sensitivities in the insurance sector.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
